Johns Hopkins Researchers Patent Enhanced Mebendazole Formulation for Cancer Treatment
核心洞察
Johns Hopkins University researchers have patented a new crystal form of mebendazole called polymorph C (搜索) that demonstrates superior tumor penetration compared to standard formulations.
The enhanced formulation can effectively cross the blood-brain barrier and reach brain tumors (搜索) at therapeutic concentrations, addressing a major challenge in treating brain cancers.
Preclinical studies in mice showed polymorph C (搜索) achieved increased tumor suppression with acceptable toxicity across multiple cancer types including gliomas (搜索), breast, colon, and pancreatic cancers.
Researchers at Johns Hopkins University have developed and patented a novel crystal form of the decades-old antiparasitic drug mebendazole that shows enhanced anticancer properties, potentially offering new treatment options for patients with hard-to-treat malignancies including brain tumors (搜索).
The patented formulation, designated polymorph C (搜索), represents a significant advancement over standard mebendazole preparations. According to the patent awarded on September 7, 2021, an oral formulation containing at least 90 percent polymorph C can reach cancer cells at higher concentrations than conventional mebendazole formulations.
Enhanced Tumor Penetration and Brain Delivery
The key breakthrough lies in polymorph C (搜索)'s ability to effectively cross the blood-brain barrier, a protective mechanism that typically prevents most chemotherapy drugs from reaching brain tumors (搜索). In preclinical experiments with mice, polymorph C achieved effective concentrations within tumors and demonstrated stronger tumor-suppressing effects compared to other mebendazole forms.
"As an oral drug, mebendazole polymorph C (搜索) is a superior form, and it reaches the brain and brain tumors (搜索) in effective concentrations," the patent states. "Efficacy is further improved by combining mebendazole with a P-glycoprotein (搜索) inhibitor."
The research team, led by Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut Joshi, and Tara Williamson, found that even after a single oral dose, the drug maintained brain concentrations for several hours at levels higher than those needed to kill cancer cells in laboratory tests.
Broad Cancer Applications
The patent covers treatment applications for a wide range of malignancies, including brain tumors (搜索) such as gliomas (搜索) and medulloblastomas (搜索), as well as breast, colon, lung, pancreatic, thyroid cancers, melanoma (搜索), and sarcomas. The inventors also suggest potential use as a chemopreventative agent for individuals at high risk of developing cancer.
Recent preclinical studies confirmed that polymorph C (搜索) not only reaches high concentrations in the brain but also effectively concentrates within brain tumors (搜索), significantly improving survival in mice with gliomas (搜索) and medulloblastomas (搜索) compared to standard formulations.
Combination Therapy Strategies
The researchers explored combination approaches to further enhance therapeutic efficacy. Testing polymorph C (搜索) with elacridar, a drug that blocks cancer cells' molecular pumps that expel therapeutic agents, showed extended survival in mice with aggressive brain tumors (搜索) compared to polymorph C alone.
The patent also describes pairing polymorph C (搜索) with anti-inflammatory drugs such as celecoxib or sulindac. Since chronic inflammation is linked to cancer development, this combination could help reduce tumor formation risk in vulnerable populations.
Safety Profile and Development Advantages
Mebendazole's established safety record, with approval dating back to the early 1970s, provides a significant advantage for clinical development. The drug is well-understood by physicians and even available over-the-counter in some countries, potentially allowing researchers to focus on testing cancer efficacy rather than establishing basic safety parameters.
However, the research team noted important limitations. Prolonged treatment combining mebendazole and elacridar caused side effects including significant weight loss and mortality in some mice, highlighting the need for careful dosing optimization in future studies.
Clinical Translation Challenges
While the preclinical results are promising, the researchers acknowledge that positive outcomes in mice do not guarantee human efficacy. Clinical development will require determining appropriate dosing regimens, understanding human metabolism patterns, and evaluating potential drug interactions.
The patent describes various formulation approaches, including granulated, coated, and micronized versions designed to improve drug absorption, all requiring further development before clinical testing.
Traditional mebendazole has faced challenges with inconsistent absorption in the body, but the polymorph C (搜索) formulation is specifically designed to overcome this limitation. If clinical trials confirm the preclinical promise, mebendazole polymorph C could represent a rare example of an effective, affordable cancer therapy based on a drug already trusted by healthcare providers.